Barhemsys (Amisulpride) Patent Expiration, LOE Window & CMS Spending

Barhemsys (Amisulpride) by Lxo Ireland Designated Activity: FDA Orange Book LOE 2038-02-09, 0 AB generics, $110K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLxo Ireland Designated Activity
FDA Application & PathwayN209510 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-02-09
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$110K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$110K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel